The content on this site is intended for healthcare professionals only
At the 1st Immunotherapy of Cancer Conference ( ITOC ) at a sponsored symposium supported by BMS Professor Romero describes how tumours can evade the immune system and thereby survive and proliferate.
Professor Romero provides an overview of the relevant cell types and complex signalling pathways involved in this evasion.
He then goes on to discuss that there are numerous potential strategies to overcome tumour immune evasion mechanisms which could potentially provide long-term survival benefit for patients.
To view the slides fullscreen click the square and arrows button at the bottom right of the player.
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
